Endocrinology Unit, University of Melbourne, Western Hospital, Footscray, Victoria, Australia.
J Bone Miner Res. 2011 Jun;26(6):1377-9. doi: 10.1002/jbmr.308.
This case describes a man with an unusual cause of an atypical subtrochanteric fracture, pycnodysostosis. This condition results from mutations involving the cathepsin K gene. New antiresorptive treatments for osteoporosis inhibit the cathepsin K enzyme in osteoclasts. Therefore, there should be vigilant monitoring for the development of long-term complications noted to occur in diseases of reduced osteoclast function, including pycnodysostosis, in patients receiving these novel antiresorptive agents.
本病例描述了一名男性患者,其发生了一种不典型的转子下骨折,即干骺端发育不良症。这种情况是由涉及组织蛋白酶 K 基因的突变引起的。用于治疗骨质疏松症的新型抗吸收药物可抑制破骨细胞中的组织蛋白酶 K 酶。因此,在使用这些新型抗吸收药物的患者中,应警惕监测可能发生的与破骨细胞功能降低的疾病相关的长期并发症,包括干骺端发育不良症。